BioXcel Therapeutics, a US-based pharmaceutical company, specializes in developing innovative drugs using artificial intelligence (AI) technology for environmental, sustainability, and governance (ESG) purposes. With an ESG score of 27.6, the company is considered to have a medium risk assessment. Its pipeline includes products like BXCL501 and BXCL701, with IGALMI (BXCL501) being the first FDA-approved sublingual film for treating agitation in adults with schizophrenia or bipolar disorders.